Effect of aglepristone ( Ru 534 ) on the Ki 67 proliferation index of spontaneous canine mammary tumours
L. B. Broenden,N. Toft,T. Knudsen,J. Mikkelsen,A. Kristensen,V. Domingo,C. Recuerda,E. Rollón,Y. Millán,I. Barranco,-. J.Gómez,Laguna,J. M. Mulas
Abstract:s presented at the ESVONC spring meeting, Cambridge, UK, 23–25 March 2007 Veterinary and Comparative Oncology is pleased to include these abstract titles from the Annual Conference and we hope you fi nd them informative and useful. These abstracts have not been subjected to peer review or editorial revision however, and it would be prudent for the reader to exercise caution in the interpretation of the data presented. The abstracts published in this proceedings should be treated as personal communications and should be cited as such. Telomerase targeted cancer gene therapy in canines M. L. Arendt, J. Morris, L. Nasir, I. M. Morgan University of Glasgow, Faculty of Veterinary Medicine, Bearsden Road, G61 1QH, Glasgow, UK In cancer gene therapy there are basic elements that need to be accomplished in order to produce an effective therapy. These are specifi c targeting of cancer cells, high expression of trans-genes and low toxicity. We have used the telomerase promoter which is shown to be active in 85–90% of canine cancers and combined this with a two-step amplifi cation mechanism. In this system the telomerase promoter drives the transcription of a transcriptional activator protein which in turn activates a strong minimal promoter to transcribe the trans-gene of interest. We have tested this system in cell culture using telomerase positive and negative cell lines and have shown the ability of this system to be very active in telomerase positive cells. We have also compared our system with the GAL4-VP16 system which is commonly used in gene therapy. Results: Our system shows a high level of specifi city and sensitivity and it is superior to the GAL4-VP16 system. Conclusion: We have developed a system with a unique potential to target cancer cells and express trans-genes at a high level and believe that this system will be able to improve gene therapy mechanisms. Prospect: We are working on developing a conditionally replicative adenovirus using CAV-1 making it capable of replicating and inducing lysis in telomerase positive cells. Simultaneously we are on using the TRAIL gene for cancer cell killing. 66 Conference Proceedings Journal compilation © 2008 Blackwell Publishing Ltd, Veterinary and Comparative Oncology, 6, 1, 65–83 (doi: 10.1111/j.1476-5829.2007.00151.x) Most frequently encountered neoplasia in dogs in Denmark: data from the Danish Veterinary Cancer Registry L. B. Broenden, N. Toft, T. Knudsen, J. Mikkelsen, A. T. Kristensen Department of Small Animal Clinical Sciences, Faculty of Life Sciences, Dyrlaegevej 16, 1870 Frederiksberg C, Denmark Introduction: During the last 2.5 years a group of practitioners representing initially a few practices but lately 30 practices throughout Denmark have entered diagnosed cases in dogs to the Danish Veterinary Cancer Registry. A total of 977 cases from dogs have been reported. A legally required registry of the country’s 600 000 dogs allows for weighing of the numbers of cases within a certain breed against the number of dogs of that particular breed in Denmark and estimation of relative risk. Objective and method: The objective of the current study was to estimate prevalence of the most common neoplasia in dogs in Denmark and the relative risk of neoplasia in different breeds. Results: Based on the registry data, at present the most common neoplasia in Danish dogs were cutaneous (394; 40%) followed by mammary (185; 19%), haemolymphatic tissues (52; 5%) and oral cavity (40; 4%). The most frequently encountered malignant cancers were mast cell tumours (76; 8%), adenocarcinoma (72; 7%), lymphoma (68; 7%) and carcinoma (63; 6%). Benign tumours most commonly entered in the registry were lipomas (123; 13%), adenomas (75; 8%), and histiocytomas (73; 7%). The relative risk of neoplasia for the breeds most commonly seen (relative risk estimates regulated for population composition) was highest in Boxers (4.38), Bernese Mountain dogs (2.50), Flat coated retrievers (1.88), and Cocker spaniels (1.75). Conclusion: These results correspond well with data from a similar study in Norway, except with regard to haemolymphatic neoplasia and the order of breeds with high relative risk is slightly different. Reference 1. Arnesen K, Gamlem H, Glattre E, Grøndalen J, Moe L, Nordstoga K. Hundekreftregisteret i Norge 1990–1998. Norsk Veterinærtidskrift 2000; 112: 137–147. Effect of aglepristone (Ru534) on the Ki67 proliferation index of spontaneous canine mammary tumours V. Domingo, C. Recuerda, E. Rollón, Y. Millán, I. Barranco, J. GómezLaguna, J. Martín de las Mulas Clinica Veterinaria Recuerda, Granada, Spain, Clinica Veterinaria Canymar, Cadiz, Spain, Depto. de A. y Anatomía Patológica Comparada, Facultad de Veterinaria, Universidad de Córdoba, Spain Introduction: Progesterone receptor (PR) activation plays an important role in the development and growth of canine mammary tumours. The aim of this study was to investigate whether aglepristone has any effect on the proliferation rate of canine mammary tumour cells. Conference Proceedings 67 Journal compilation © 2008 Blackwell Publishing Ltd, Veterinary and Comparative Oncology, 6, 1, 65–83 (doi:10.1111/j.1476-5829.2007.00151.x) Methods: With the owner’s consent, 12 bitches with malignant mammary tumours were injected with aglepristone (10 mg/kg, subcutaneously) on days 1, 2, 7 and 8. Both the pre-treatment biopsy (day 1) and the surgical excision specimen (day 15) were processed routinely for histopathology and immunohistochemistry (oestrogen receptor α –ERα -, PR, MIB1 antigen) studies. Blood samples were collected on days 1 and 15 to assay plasma concentrations of progesterone. The size of the tumour was recorded before the beginning of the treatment and then on days 8 and 15. Six bitches without tumours were equally treated and served as controls. Results: All 12 tumours analyzed were classifi ed as carcinomas, and 9 expressed both ERα and PR (75%). The Ki67 proliferation index (number of positive cells/1000 cells) was lower in the post-treatment biopsy of 6 cases with and 2 cases without hormone receptors expression. No decrease in the number of MIB1-positive cells was observed in tissues from control dogs. Plasma concentrations of progesterone increased in experimental but not in control dogs. No changes were observed in the size of the tumours, neither in the hormone receptor expression pattern, after the treatment. Conclusions: Aglepristone diminished Ki67 cell proliferation index and progesterone levels but not on tumour size or hormone receptor expression. Comparison of staging in dogs with appendicular osteosarcoma with radiographs and staging based on computed tomography N. Eberle, D. Simon, A. Gerdwilker, M. Fork, I. Nolte Small Animal Hospital, School of Veterinary Medicine Hannover, Germany Introduction: Conventional staging of appendicular osteosarcoma in the dog is based on radiographs of the primary tumour and thorax. Examination by computed tomography (CT) is a diagnostic technique increasingly available in veterinary medicine. It was the aim of this study to compare staging performed with conventional methods to staging based on CT examination with special emphasis on the detection of pulmonary metastases of osteosarcoma as well as to analyse the data with regards to its prognostic value. Methods: All canine patients cytologically or histologically diagnosed with appendicular osteosarcoma were included into the study. All dogs underwent radiographic examination as well as CT examination of the primary lesion and the thoracic cavity. Data recorded included epidemiologic data, conventional clinical stage and computed tomography fi ndings. Kaplan–Meier product limited analysis was used for survival analysis. Cox forward multivariate regression analysis was used to evaluate patient variables for infl uence on survival time. Results: 38 dogs were included in the analysis. Radiographically pulmonary lesions were detected in 2 cases (5%), whereas the CT imaging showed that pulmonary nodules were evident in 10 cases (26%). There was a signifi cantly improved detection of small pulmonary nodules in the lung parenchyma with computed tomography and better prognostic assessment of clinical stage. Conclusion: Computed tomography examinations allow improved assessment of clinical stage of canine osteosarcoma patients. Although radiography is used in diagnosis of canine osteosarcoma, additional imaging with computed tomography seems benefi cial in the detection of pulmonary lesions. 68 Conference Proceedings Journal compilation © 2008 Blackwell Publishing Ltd, Veterinary and Comparative Oncology, 6, 1, 65–83 (doi: 10.1111/j.1476-5829.2007.00151.x) Impact of Ki67 labelling index on treatment outcome of feline vaccine-associated sarcoma C. Eckstein, C. Rohrer Bley, F. Guscetti, M. Roos, B. Kaser-Hotz Diagnostic Imaging and Radio-Oncology, Vetsuisse Faculty University of Zurich, Winterthurerstrasse 260, CH-8057 Zurich, Switzerland Introduction: Feline vaccine-associated sarcomas are highly invasive and often rapidly growing neoplasms. High tumour proliferation has been shown to correlate with aggressive behaviour in human and canine soft tissue sarcomas. Methods: We evaluated the growth fraction of vaccine-associated sarcomas by Ki67 immunohistochemistry in relation to outcome after therapy, stating the hypothesis that a high labelling index implicates a less favourable response to treatment. Results: Median survival of the 46 curatively treated patients (surgery followed by defi nitive radiation therapy) was 43 months with almost 50% of the cats becoming long-term survivors. The median progression free interval (PFI) was 37 months. In the group of palliatively treated cats (n = 27) the median survival was 24 months, with a median PFI of 10 months. Median survival of 7 months (PFI 4 months) was signifi cantly shorter in palliatively irradiated gross tumour than seen after treatment of presumed microscopic disease (survival of 30, PFI